Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Sponsors
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Those who agree to take part in the test and sign the informed consent form voluntarily; 2. Adults aged >=18years old, male or female; 3. The inpatients with mild or common type of COVID-19 confirmed according to the diagnostic criteria "COVID-19 diagnosis and treatment plan - Sixth trial edition" issued by the National Health Commission. 4. Respiratory Specimens (including but not limited to sputum, nasopharyngeal swab and secretion of lower respiratory tracts) are positive for 2019-nCoV nucleic acid by real-time fluorescent RT-PCR; or respiratory specimens are genetically sequenced and highly homologous to known 2019-nCoV.
Exclusion criteria
Exclusion criteria: 1. Participation in the study is not in accordance with the rights and interests of the patient based on PIs judgement, or any other circumstances that investigators consider inappropriate for participation; 2. With bleeding or bleeding associated with severe coagulation disorders (except for disseminated intravascular coagulation unrelated to heparin therapy), with a history of severe type II heparin-induced thrombocytopenia, whether or not caused by unfractionated heparin or low-molecular-weight heparin (significantly reduced by platelet count previously), active peptic ulcer or organ damage with bleeding tendency, clinically significant active bleeding , cerebral hemorrhage; 3. Have any situation that treatment with low molecular heparin is required; 4. Females who are pregnant or likely to be pregnant, or who are lactating and unable to stop breastfeeding, or who have positive pregnancy tests during screening; 5. Males or females who have a birth plan or are unwilling to take reliable contraceptive measures for contraception within 90 days from signing the informed consent to the last dose; 6. With severe liver disease: patient with basic diseases of liver cirrhosis , or alanine aminotransferase (ALT) / aspartate aminotransferase (AST) increased more than 5 times of the normal upper limit; 7. Patients known to have severe renal impairment [creatinine clearance (CcCl) < 30 ml / min], or to receive continuous renal replacement therapy, hemodialysis or peritoneal dialysis; 8. At rest without oxygen inhalation, SPO2 <=93%, or PaO2/ FiO2 <=300 mmHg; 9. Patients allergic to enoxaparin, heparin or its derivatives, including other low-molecular-weight heparins.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to Virus Eradication; | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of mild or common novel coronavirus pneumonia progressing to severe;Time for the main clinical manifestations to subside (fever, cough, respiratory rate, SPO2 ); | — |
Countries
China
Contacts
Public ContactZhang Yu
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
Outcome results
None listed